Atara Biotherap | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 3.453 M

Revenue: As of FY2025 Q3, the actual value is USD 3.453 M, beating the estimate of USD 2.739 M.

EPS: As of FY2025 Q3, the actual value is USD -0.32, beating the estimate of USD -0.692.

EBIT: As of FY2025 Q3, the actual value is USD -2.869 M.

Segment Revenue

• Commercialization Revenue: For the three months ended September 30, 2025, revenue was $3.5 million, a decrease from $40.2 million in the same period in 2024. For the nine months ended September 30, 2025, revenue was $119.2 million, an increase from $96.2 million in 2024.

Operational Metrics

• Net Income (Loss): For the nine months ended September 30, 2025, net income was $36.1 million, compared to a net loss of - $72.7 million in the same period in 2024.
• Research and Development Expenses: For the three months ended September 30, 2025, expenses were $2.9 million, a decrease from $43.9 million in 2024. For the nine months ended September 30, 2025, expenses were $37.7 million, down from $122.8 million in 2024.
• General and Administrative Expenses: For the three months ended September 30, 2025, expenses were $4.0 million, a decrease from $10.4 million in 2024. For the nine months ended September 30, 2025, expenses were $22.0 million, down from $30.4 million in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was - $45.2 million, compared to - $44.2 million in 2024.
• Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided was $9.7 million.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided was $16.1 million.

Future Outlook and Strategy

• Core Business Focus: Atara Biotherapeutics plans to continue the development of its lead program, tab-cel, which is in Phase 3 clinical development in the U.S. and has received marketing authorization in the EEA, UK, and Switzerland. The company is focused on transferring all manufacturing and development responsibilities to Pierre Fabre.
• Non-Core Business: The company has paused development of its allogeneic CAR T cell programs and discontinued development operations for its CAR T programs, including all clinical trials evaluating ATA3219 and development operations for ATA3431. Atara has also returned the rights to the ATA188 and EBV Vaccine programs to QIMR.